Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Xenetic Biosciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $8.68 Mil. Xenetic Biosciences's Total Assets for the quarter that ended in Mar. 2024 was $9.39 Mil.
Therefore, Xenetic Biosciences's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.92.
The historical rank and industry rank for Xenetic Biosciences's Equity-to-Asset or its related term are showing as below:
XBIO'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.28 Med: 0.77 Max: 0.95
Current: 0.92
During the past 13 years, the highest Equity to Asset Ratio of Xenetic Biosciences was 0.95. The lowest was 0.28. And the median was 0.77.
XBIO's Equity-to-Asset is ranked better than 89.74% of 1559
companies
in the Biotechnology industry
Industry Median: 0.67
vs XBIO: 0.92
Xenetic Biosciences Equity-to-Asset Historical Data
The historical data trend for Xenetic Biosciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Xenetic Biosciences's Equity-to-Asset
For the Biotechnology subindustry, Xenetic Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenetic Biosciences's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Xenetic Biosciences's Equity-to-Asset falls into.
Xenetic Biosciences Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Xenetic Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Xenetic Biosciences Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Xenetic Biosciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Xenetic Biosciences (Xenetic Biosciences) Business Description
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XBIO has been successfully added to your 